TY - JOUR
T1 - Comprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology
AU - Kairemo, Kalevi
AU - Wang, Wei Lien
AU - Subbiah, Vivek
N1 - Funding Information:
This study was funded by Shanon Wilkes Research Foundation. The University of Texas MD Anderson Cancer Center is funded by NIH/NCI Cancer CenterSupport Grant P30 CA016672.
Funding Information:
funding this study was funded by shanon Wilkes research Foundation. the University of texas MD anderson Cancer Center is funded by NIH/NCI Cancer Centersupport Grant p30 Ca016672 .
Publisher Copyright:
© 2019 BMJ Publishing Group Limited.
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Malignant transformation of giant cell tumour of the bone is extremely rare. In addition, bone transformation in giant cell tumour may occur in different phases. With conventional X-rays, CT scans or MRIs, it may be challenging to distinguish among different phases of bone transformation, normal bone, soft tissue disease and bone disease (benign vs malignant lesions) and changes in multiple organs such as lung, liver and lymph nodes unless every lesion is biopsied, which is not practical. Molecular imaging with different isotopes (Tc-99m phosphonate, 2-deoxy-2-(18 F)fluoro-d-glucose and sodium fluoride-18) may help to better characterise the disease. We hypothesised that molecular imaging could offer qualitative and quantitative characterisation of all stages of bone formation, destruction, reactivity or neoplasia in a patient with giant cell tumour of the bone, and we present the first case of molecular imaging where bone formation was seen in multiple soft tissues, such as lungs, muscles, lymph nodes and liver.
AB - Malignant transformation of giant cell tumour of the bone is extremely rare. In addition, bone transformation in giant cell tumour may occur in different phases. With conventional X-rays, CT scans or MRIs, it may be challenging to distinguish among different phases of bone transformation, normal bone, soft tissue disease and bone disease (benign vs malignant lesions) and changes in multiple organs such as lung, liver and lymph nodes unless every lesion is biopsied, which is not practical. Molecular imaging with different isotopes (Tc-99m phosphonate, 2-deoxy-2-(18 F)fluoro-d-glucose and sodium fluoride-18) may help to better characterise the disease. We hypothesised that molecular imaging could offer qualitative and quantitative characterisation of all stages of bone formation, destruction, reactivity or neoplasia in a patient with giant cell tumour of the bone, and we present the first case of molecular imaging where bone formation was seen in multiple soft tissues, such as lungs, muscles, lymph nodes and liver.
KW - cancer intervention
KW - carcinogenesis
KW - radiology
KW - screening (oncology)
UR - http://www.scopus.com/inward/record.url?scp=85064978804&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064978804&partnerID=8YFLogxK
U2 - 10.1136/bcr-2016-218839
DO - 10.1136/bcr-2016-218839
M3 - Article
C2 - 31015231
AN - SCOPUS:85064978804
SN - 1757-790X
VL - 12
JO - BMJ Case Reports
JF - BMJ Case Reports
IS - 4
M1 - e218839
ER -